文献速递产科

氨甲环酸预防剖宫产产后出血的更新荟萃分析

Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2021-09-25

该更新荟萃分析纳入36项随机对照试验共10659名剖宫产女性,比较预防性静脉氨甲环酸与安慰剂(均接受标准宫缩剂)的效果。氨甲环酸显著降低总失血量、血红蛋白下降幅度、失血>1000 mL风险、输血需求及额外宫缩剂需求。作者认为预防性氨甲环酸有效,但高危人群疗效与安全性仍需进一步研究。

要点

  • 剖宫产预防性氨甲环酸可显著减少总失血量与血红蛋白下降。
  • 氨甲环酸降低失血>1000 mL、输血及额外宫缩剂需求的风险。
  • 证据质量:总失血量与血红蛋白变化为中等,其他结局为低。

核心结论

  • 预防性氨甲环酸可有效减少剖宫产女性产后失血并限制血红蛋白下降。
  • 其在高危人群中的疗效及安全性仍需进一步研究验证。

研究设计与样本

  • 纳入36项随机对照试验,共10659名剖宫产女性。
  • 比较静脉氨甲环酸与安慰剂,受试者均接受标准预防性宫缩剂。
  • 检索MEDLINE、Scopus、Web of Science、Cochrane CENTRAL、ClinicalTrials.gov及Google Scholar,自建库至2021年6月30日。
  • 采用RoB 2工具评估偏倚风险,拟合限制性最大似然随机效应模型进行荟萃分析。
  • 按国家、方案可得性、双盲、偏倚风险、样本量及氨甲环酸剂量进行亚组分析。

主要发现

  • 氨甲环酸组总失血量显著更低(均数差-189.44 mL;95%CI -218.63至-160.25)。
  • 血红蛋白下降幅度显著更低(均数差8.22%;95%CI 5.54-10.90)。
  • 失血>1000 mL风险降低(OR 0.37;95%CI 0.22-0.60)。
  • 输血需求降低(OR 0.41;95%CI 0.26-0.65),额外宫缩剂需求降低(OR 0.36;95%CI 0.25-0.52)。
  • 亚组分析提示在中低收入国家氨甲环酸减少总失血量的效应更大。

关键数值与推荐

  • 总失血量均数差-189.44 mL(95%CI -218.63至-160.25)。
  • 血红蛋白下降均数差8.22%(95%CI 5.54-10.90)。
  • 失血>1000 mL的OR 0.37(95%CI 0.22-0.60)。
  • 输血的OR 0.41(95%CI 0.26-0.65)。
  • 额外宫缩剂的OR 0.36(95%CI 0.25-0.52)。

临床怎么用

  • 对接受标准宫缩剂预防的剖宫产女性,可考虑预防性静脉氨甲环酸以减少失血与血红蛋白下降。
  • 用于低出血风险人群时结局稳定,但高危人群的疗效与安全性尚需研究。
  • 临床决策应结合证据质量分级,总失血量与血红蛋白变化证据为中等,其他结局为低。

局限性

  • 高危人群中的疗效尚未验证,安全性特征仍需进一步研究确认。
  • 总失血量与血红蛋白百分比变化之外的结局证据质量被评为低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to assess the efficacy and safety of prophylactic tranexamic acid administration vs standard uterotonic agents alone among women undergoing cesarean delivery. DATA SOURCES: MEDLINE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar were systematically searched from inception to June 30, 2021. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing intravenous tranexamic acid administration with placebo in women undergoing cesarean delivery and receiving standard prophylactic uterotonic agents were held eligible. STUDY APPRAISAL AND SYNTHESIS METHODS: The risk of bias of individual studies was appraised with the Risk of Bias 2 tool. Meta-analysis was conducted by fitting random-effects models using restricted maximum likelihood. Subgroup analysis was performed on the basis of country, protocol availability, double-blinding, risk of bias, sample size, and tranexamic acid dose. A 1-stage meta-analysis was performed as a sensitivity analysis. The credibility of outcomes was appraised with the Grading of Recommendations Assessment, Development and Evaluation approach. RESULTS: Overall, 36 studies with 10,659 women were included. Tranexamic acid administration was associated with significantly lower total blood loss (mean difference, -189.44 mL; 95% confidence intervals, -218.63 to -160.25), lower hemoglobin drop (mean difference, 8.22%; 95% confidence interval, 5.54-10.90), decreased risk of blood loss of >1000 mL (odds ratio, 0.37; 95% confidence interval, 0.22-0.60), transfusion requirement (odds ratio, 0.41; 95% confidence interval, 0.26-0.65), and need of additional uterotonics (odds ratio, 0.36; 95% confidence interval, 0.25-0.52). Subgroup analysis indicated a greater effect of tranexamic acid on total blood loss reduction in low-middle income countries. The outcomes remained stable by separately evaluating women at low bleeding risk. The 1-stage meta-analysis demonstrated similar outcomes with the primary analysis. The quality of evidence was judged to be moderate regarding total blood loss and hemoglobin percentage change and low for the other outcomes. CONCLUSION: This meta-analysis suggested that prophylactic tranexamic acid administration is effective among women undergoing cesarean delivery in lowering postpartum blood loss and limiting hemoglobin drop. Further research is needed to test its efficacy in high-risk populations and verify its safety profile.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bellos I, Pergialiotis V. Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis. Am J Obstet Gynecol. 2021. PMID: 34582795. doi:10.1016/j.ajog.2021.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。